Top Left: (from left to right) OHC CEO Silas Buchanan with Dr. Elizabeth Ofili of Morehouse School of Medicine, Esther Krofah of Milken Institute, FasterCures, and Dr. Shari Ling of the Centers for Medicare and Medicaid Services (CMS); Top Right: Buchanan and Krofah; Bottom Left: Jen Goldsack, CEO of Digital Medicine Society (DiMe) and Buchanan; Bottom Right: Buchanan with Monica Bertagnolli, M.D., Director of the National Institutes of Health (NIH), and Robert Califf, M.D., Commissioner of Food and Drugs for the Food and Drug Administration (FDA).
[30 Second Overview]:
Diversity and Hope in Clinical Trials: The White House Clinical Trials Forum highlighted the importance of diverse participation to ensure effective treatments and provide hope for those with rare conditions and limited options.
Challenges and Progress: While digitization has improved accessibility to clinical trials, barriers like travel burdens and costs still restrict many potential participants.
Collaborative Efforts for Better Health Outcomes: The forum emphasized the need for public and private sector collaboration to create inclusive systems that accelerate innovation and improve health outcomes for everyone.
The White House Clinical Trials Forum on June 26, 2024, provided an invaluable opportunity for passionate and like-minded individuals to explore the vital link between clinical trials and health outcomes.
This event highlighted the significance of ensuring diversity among trial participants, emphasizing that clinical trials offer not just treatment, but hope, particularly for those with rare conditions and limited options.
Diversity and Inclusivity in Clinical Trials
A key discussion point was the importance of inclusivity in clinical trials. Diverse participation ensures that treatments are effective across different populations, leading to better health outcomes for all.
The digitization of medical records has made clinical trials more accessible, allowing researchers to reach a broader demographic. However, challenges such as travel burdens and costs remain significant barriers for many potential participants.
Collaboration in Clinical Trials
An overarching theme of the forum was our shared humanity and the unique experiences we bring to this critical work.
To develop sustainable solutions and best practices, collaboration between the public and private sectors is essential. By building systems that foster cooperation and bridge gaps, we can disseminate innovation widely, ensuring no one is left behind.
OHC CEO Silas Buchanan Attends White House Event on Clinical Research Diversity
OHC’s CEO, Silas Buchanan, was invited to attend the event at the White House, offering him a front seat to the two panel discussions included in the opening session.
“I am honored to have been invited to the White House to discuss real solutions to the very real problems of engaging diverse communities in clinical research,” Buchanan said.
He was able to share his input first-hand following the opening session when all attendees broke into small groups for a private closed-door discussion session. During this time, invitees discussed best practices and solutions to strive for in reaching their collective vision of diverse and inclusive clinical trials that are accessible and attainable for all who need them.
Takeaways
The White House Clinical Trials Forum underscored the need for a collective effort to enhance clinical trial accessibility and effectiveness, striving for a future where advancements in health are available to all.
“While we have made some progress, well-earned and persistent lack of trust by communities of color in the healthcare and research ecosystem must be acknowledged,” Buchanan said. “Today was a good start to meaningfully assuring equity in healthcare generally and Clinical Research, specifically.”
Learn more by watching the White House Clinical Trials Forum opening session on YouTube.
Comentarios